TLR4 and glioma: In contrast to the effects of targeting fulvestrant, the effects of targeting TLR4 signaling, which is specifically inhibited by CLI-095 (TAK242), have been proven to be significantly effective in inhibiting or blocking cell invasion and metastasis in many malignant tumors, such as ovarian cancer, breast cancer and glioma [42, 43].